Brief History of Opioids in Perioperative and Periprocedural Medicine to Inform the Future

REFERENCES

1. 1.↵
   1. Keys TE

   . The History of Surgical Anesthesia. Schuman's; 1945.
2. 2.↵
   1. Foldes FF

   . Narcotics and narcotic antagonists: chemistry, pharmacology, and applications in anesthesiology and obstetrics (American lecture series, publication … in American lectures in anesthesiology). Thomas; 1964.
3. 3.↵
   1. Macht DI

   . The history of opium and some of its preparations and alkaloids. JAMA. 1915;LXIV(6):477-481. doi: 10.1001/jama.1915.02570320001001

   OpenUrlCrossRef
4. 4.↵
   1. Corssen G,
   2. Reves JG,
   3. Stanley TH

   . Intravenous Anesthesia and Analgesia. Lea & Febiger; 1988.
5. 5.↵
   1. Brummett CM,
   2. Waljee JF,
   3. Goesling J,
   4. et al.

   New persistent opioid use after minor and major surgical procedures in US adults [published correction appears in JAMA Surg. 2019;154(3):272]. JAMA Surg. 2017;152(6):e170504. doi: 10.1001/jamasurg.2017.0504

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Sertürner FWA

   . Ueber das Morphium, eine neue salzfähige Grundlage, und die Mekonsäure, als Haupbestandteile des Opiums. Ann Phys. 1817;55(1):56-89. doi: 10.1002/andp.18170550104

   OpenUrlCrossRef
7. 7.↵
   1. Warolin C

   . Pierre-Jean Robiquet: (Rennes, 14 janvier 1780 – Paris, 29 avril 1840) [Pierre-Jean Robiquet]. Rev Hist Pharm (Paris). 1999;47(321):97-110. doi: 10.3406/pharm.1999.4935

   OpenUrlCrossRef
8. 8.↵
   1. Wisniak J

   . Pierre-Jean Robiquet. Educ Quim. 2013;24(1):139-149. doi: 10.1016/S0187-893X(13)72507-2

   OpenUrlCrossRef
9. 9.↵
   1. Bolser DC,
   2. Davenport PW

   . Codeine and cough: an ineffective gold standard. Curr Opin Allergy Clin Immunol. 2007;7(1):32-36. doi: 10.1097/ACI.0b013e3280115145

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Craig R

    . A history of syringes and needles. Faculty of Medicine, The University of Queensland. December 20, 2018. Accessed July 15, 2022. medicine.uq.edu.au/blog/2018/12/history-syringes-and-needles
11. 11.↵
    Francis Rynd (1801-1861). JAMA. 1970;212(7):1208. doi: 10.1001/jama.1970.03170200072016

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Zakon SJ

    . The centenary of the hypodermic syringe, 1853-1953. AMA Arch Derm Syphilol. 1953;68(5):591. doi: 10.1001/archderm.1953.01540110113025

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Sexton JC

    . Death following scopolamine-morphine injection. Lancet Clin. 1905;55:582.

    OpenUrl
14. 14.↵
    1. Wright CRA

    . XLIX.–On the action of organic acids and their anhydrides on the natural alkaloids. Part 1. J Chem Soc. 1874;27:1031-1043. doi: 10.1039/JS8742701031

    OpenUrlCrossRef
15. 15.↵
    1. Eger EI II.,
    2. Saidman LJ,
    3. Westhorpe RN

    1. Stanley TH

    . The history of opioid use in anesthetic delivery. In: Eger EI II., , Saidman LJ, , Westhorpe RN, eds. The Wondrous Story of Anesthesia. Springer; 2014:641-659.
16. 16.↵
    1. Reichle CW,
    2. Smith GM,
    3. Gravenstein JS,
    4. Macris SG,
    5. Beecher HK

    . Comparative analgesic potency of heroin and morphine in postoperative patients. J Pharmacol Exp Ther. 1962;136:43-46.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Lundy JS

    . Balanced anesthesia. Minn Med. 1926;9:399.

    OpenUrl
18. 18.↵
    1. Lundy JS

    . Useful anesthetic agents and methods. JAMA. 1931;97(1):25-31. doi: 10.1001/jama.1931.27310010003010

    OpenUrlCrossRef
19. 19.↵
    1. Crile GW

    . Phylogenetic association in relation to certain medical problems. Bost Med Surg J. 1910; 163(24):893-904. doi: 10.1056/NEJM191012151632401

    OpenUrlCrossRef
20. 20.↵
    1. Pope JE,
    2. Deer TR,
    3. Amirdelfan K,
    4. McRoberts WP,
    5. Azeem N

    . The pharmacology of spinal opioids and ziconotide for the treatment of non-cancer pain. Curr Neuropharmacol. 2017;15(2):206-216. doi: 10.2174/1570159x14666160210142339

    OpenUrlCrossRef
21. 21.↵
    1. Covvey JR

    . Recent developments toward the safer use of opioids, with a focus on hydrocodone. Res Social Adm Pharm. 2015;11(6):901-908. doi: 10.1016/j.sapharm.2015.02.001

    OpenUrlCrossRef
22. 22.↵
    U.S. Food and Drug Administration. Drugs@FDA-Approved Drugs: Hydrocodone. Accessed July 16, 2022. www.accessdata.fda.gov/scripts/cder/daf/index.cfm
23. 23.↵
    1. Brotman M,
    2. Cullen SC

    . Supplementation with Demerol during nitrous oxide anesthesia. Anesthesiology. 1949;10(6):696-705. doi: 10.1097/00000542-194911000-00005

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Mushin WW,
    2. Rendell-Baker L

    . Pethidine as a supplement to nitrous oxide anaesthesia. Br Med J. 1949;2(4625):472. doi: 10.1136/bmj.2.4625.472

    OpenUrlFREE Full Text
25. 25.↵
    1. Neff W,
    2. Mayer EC

    , Perales M de L. Nitrous oxide and oxygen anesthesia with curare relaxation. Calif Med. 1947;66(2):67-69.

    OpenUrlPubMed
26. 26.↵
    1. McEwan AI,
    2. Smith C,
    3. Dyar O,
    4. Goodman D,
    5. Smith LR,
    6. Glass PS

    . Isoflurane minimum alveolar concentration reduction by fentanyl. Anesthesiology. 1993;78(5):864-869. doi: 10.1097/00000542-199305000-00009

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Glass PS,
    2. Gan TJ,
    3. Howell S,
    4. Ginsberg B

    . Drug interactions: volatile anesthetics and opioids. J Clin Anesth. 1997;9(6 Suppl):18S-22S. doi: 10.1016/s0952-8180(97)00122-0

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Laborit H,
    2. Huguenard P

    . Pratique de l'hibernothérapie en chirurgie et en médecine. Masson & Cie; 1954.
29. 29.↵
    1. Stanley TH,
    2. Egan TD,
    3. Van Aken H

    . A tribute to Dr. Paul A. J. Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology. Anesth Analg. 2008;106(2):451-462. doi: 10.1213/ane.0b013e3181605add

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Nilsson E,
    2. Janssen P

    . Neurolept-analgesia—an alternative to general anaesthesia. Acta Anaesthesiol Scand. 1961;5:73-84. doi: 10.1111/j.1399-6576.1961.tb00085.x

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Paul D,
    2. Pick CG,
    3. Tive LA,
    4. Pasternak GW

    . Pharmacological characterization of nalorphine, a kappa 3 analgesic. J Pharmacol Exp Ther. 1991;257(1):1-7.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Miller RD

    1. Bailey PL,
    2. Egan TD,
    3. Stanley TH

    . Intravenous opioid anesthetics. In: Miller RD, ed. Anesthesia. 5th ed. Churchill Livingstone; 2000:273-376.
33. 33.↵
    1. Ngai SH,
    2. Berkowitz BA,
    3. Yang JC,
    4. Hempstead J,
    5. Spector S

    . Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology. 1976;44(5):398-401. doi: 10.1097/00000542-197605000-00008

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Stanley TH

    . The fentanyl story. J Pain. 2014;15(12):1215-1226. doi: 10.1016/j.jpain.2014.08.010

    OpenUrlCrossRef
35. 35.↵
    1. Egan TD,
    2. Lemmens HJ,
    3. Fiset P,
    4. et al.

    The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology. 1993;79(5):881-892. doi: 10.1097/00000542-199311000-00004

    OpenUrlCrossRefPubMedWeb of Science
36. 36.↵
    1. Egan TD

    . The clinical pharmacology of remifentanil: a brief review. J Anesth. 1998;12(4):195-204. doi: 10.1007/BF02481730

    OpenUrlCrossRef
37. 37.↵
    1. Stanley TH,
    2. Webster LR

    . Anesthetic requirements and cardiovascular effects of fentanyl-oxygen and fentanyl-diazepam-oxygen anesthesia in man. Anesth Analg. 1978;57(4):411-416. doi: 10.1213/00000539-197807000-00008

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Shover CL,
    2. Falasinnu TO,
    3. Dwyer CL,
    4. et al.

    Steep increases in fentanyl-related mortality west of the Mississippi River: recent evidence from county and state surveillance. Drug Alcohol Depend. 2020;216:108314. doi: 10.1016/j.drugalcdep.2020.108314

    OpenUrlCrossRef
39. 39.↵
    United States Drug Enforcement Administration. Fentanyl Awareness. April 29, 2022. Accessed September 21, 2022. dea.gov/fentanylawareness
40. 40.↵
    1. Raja SN,
    2. Lowenstein E

    . The birth of opioid anesthesia. Anesthesiology. 2004;100(4):1013-1015. doi: 10.1097/00000542-200404000-00036

    OpenUrlCrossRefPubMedWeb of Science
41. 41.↵
    1. Lowenstein E,
    2. Hallowell P,
    3. Levine FH,
    4. Daggett WM,
    5. Austen WG,
    6. Laver MB

    . Cardiovascular response to large doses of intravenous morphine in man. N Engl J Med. 1969;281(25):1389-1393. doi: 10.1056/NEJM196912182812503

    OpenUrlCrossRefPubMedWeb of Science
42. 42.↵
    1. de Castro J,
    2. Viars P

    . Utilization of central analgesics used separately in high doses in the operative period. Article in French. Anesth Analg (Paris). 1969;26(2):145-161.

    OpenUrlPubMed
43. 43.↵
    1. Aminoff MJ,
    2. Daroff RB

    1. Bristow S,
    2. Singh V,
    3. Ballantyne J

    . Opiods. In: Aminoff MJ, , Daroff RB, eds. Encyclopedia of the Neurological Sciences. 2nd ed. Academic Press; 2014:653-657.
44. 44.↵
    1. Ramos-Matos CF,
    2. Bistas KG,
    3. Lopez-Ojeda W

    . Fentanyl. StatPearls. Updated May 30, 2022. ncbi.nlm.nih.gov/books/NBK459275/
45. 45.↵
    1. Miller AL,
    2. Theodore D,
    3. Widrich J

    . Inhalational anesthetic. StatPearls. Updated September 6, 2022. ncbi.nlm.nih.gov/books/NBK554540/
46. 46.↵
    1. Cook D,
    2. Simons DJ

    . Neuromuscular blockade. StatPearls. Updated September 24, 2022. ncbi.nlm.nih.gov/books/NBK538301/
47. 47.↵
    1. Stephan BC,
    2. Parsa FD

    . Avoiding opioids and their harmful side effects in the postoperative patient: exogenous opioids, endogenous endorphins, wellness, mood, and their relation to postoperative pain. Hawaii J Med Public Health. 2016;75(3):63-67.

    OpenUrl
48. 48.↵
    1. Pappas MM,
    2. Evans B

    1. Boysen PG 2nd.

    , Pappas MM, , Evans B. An evidence-based opioid-free anesthetic technique to manage perioperative and periprocedural pain. Ochsner J. 2018;18(2):121-125. doi: 10.31486/toj.17.0072

    OpenUrlAbstract/FREE Full Text
49. 49.↵
    1. Paetzold J,
    2. Boysen PG

    . Opioid sparing anesthetic: a preliminary cost and feasibility. Anesth Analg. 2017;124(5S Suppl):947-948.

    OpenUrl
50. 50.↵
    1. Jacobs JR,
    2. Glass PS,
    3. Reves JG

    . Technology for continuous infusion in anesthesia. Int Anesthesiol Clin. 1991;29(4):39-52. doi: 10.1097/00004311-199102940-00005

    OpenUrlCrossRefPubMed
51. 51.↵
    1. Shafer SL,
    2. Stanski DR

    . Improving the clinical utility of anesthetic drug pharmacokinetics. Anesthesiology. 1992;76(3):327-330. doi: 10.1097/00000542-199203000-00001

    OpenUrlCrossRefPubMedWeb of Science
52. 52.↵
    1. Shafer SL,
    2. Varvel JR

    . Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology. 1991;74(1):53-63. doi: 10.1097/00000542-199101000-00010

    OpenUrlCrossRefPubMedWeb of Science
53. 53.↵
    1. Youngs EJ,
    2. Shafer SL

    . Pharmacokinetic parameters relevant to recovery from opioids [published correction appears in Anesthesiology. 1995;82(1):326]. Anesthesiology. 1994;81(4):833-842. doi: 10.1097/00000542-199410000-00010

    OpenUrlCrossRefPubMedWeb of Science
54. 54.↵
    1. Hughes MA,
    2. Glass PS,
    3. Jacobs JR

    . Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology. 1992;76(3):334-341. doi: 10.1097/00000542-199203000-00003

    OpenUrlCrossRefPubMedWeb of Science
55. 55.↵
    1. Chilkoti G,
    2. Wadhwa R,
    3. Saxena AK

    . Technological advances in perioperative monitoring: current concepts and clinical perspectives. J Anaesthesiol Clin Pharmacol. 2015;31(1):14-24. doi: 10.4103/0970-9185.150521

    OpenUrlCrossRefPubMed
56. 56.↵
    1. Musizza B,
    2. Ribaric S

    . Monitoring the depth of anaesthesia. Sensors (Basel). 2010;10(12):10896-10935. doi: 10.3390/s101210896

    OpenUrlCrossRefPubMedWeb of Science
57. 57.↵
    1. Yap JJ,
    2. Miczek KA

    . Stress and rodent models of drug addiction: role of VTA-accumbens-PFC-amygdala circuit. Drug Discov Today Dis Models. 2008;5(4):259-270. doi: 10.1016/j.ddmod.2009.03.010

    OpenUrlCrossRefPubMed
58. 58.↵
    1. Nestler EJ

    . Molecular basis of long-term plasticity underlying addiction [published correction appears in Nat Rev Neurosci. 2001;2(3):215]. Nat Rev Neurosci. 2001;2(2):119-128. doi: 10.1038/35053570

    OpenUrlCrossRefPubMedWeb of Science
59. 59.
    1. Robinson TE,
    2. Berridge KC

    . Review. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci. 2008;363(1507):3137-3146. doi: 10.1098/rstb.2008.0093

    OpenUrlCrossRef
60. 60.↵
    1. Pierce RC,
    2. Kumaresan V

    . The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev. 2006;30(2):215-238. doi: 10.1016/j.neubiorev.2005.04.016

    OpenUrlCrossRefPubMedWeb of Science
61. 61.↵
    1. Kalivas PW,
    2. Volkow ND

    . The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162(8):1403-1413. doi: 10.1176/appi.ajp.162.8.1403

    OpenUrlCrossRefPubMedWeb of Science
62. 62.↵
    1. Ungless MA,
    2. Magill PJ,
    3. Bolam JP

    . Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science. 2004;303(5666):2040-2042. doi: 10.1126/science.1093360

    OpenUrlAbstract/FREE Full Text
63. 63.↵
    1. Jackson ME,
    2. Moghaddam B

    . Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex. J Neurosci. 2001;21(2):676-681. doi: 10.1523/JNEUROSCI.21-02-00676.2001

    OpenUrlAbstract/FREE Full Text
64. 64.↵
    1. Belujon P,
    2. Grace AA

    . Hippocampus, amygdala, and stress: interacting systems that affect susceptibility to addiction. Ann N Y Acad Sci. 2011;1216:114-121. doi: 10.1111/j.1749-6632.2010.05896.x

    OpenUrlCrossRefPubMedWeb of Science
65. 65.↵
    1. Behrendt RP

    . Conscious experience and episodic memory: hippocampus at the crossroads. Front Psychol. 2013;4:304. doi: 10.3389/fpsyg.2013.00304

    OpenUrlCrossRef
66. 66.↵
    1. Tzschentke TM

    . The medial prefrontal cortex as a part of the brain reward system. Amino Acids. 2000;19(1):211-219. doi: 10.1007/s007260070051

    OpenUrlCrossRefPubMedWeb of Science
67. 67.↵
    1. D'Souza MS

    . Glutamatergic transmission in drug reward: implications for drug addiction. Front Neurosci. 2015;9:404. doi: 10.3389/fnins.2015.00404

    OpenUrlCrossRef
68. 68.↵
    1. Bevilacqua L,
    2. Goldman D

    . Genes and addictions. Clin Pharmacol Ther. 2009;85(4):359-361. doi: 10.1038/clpt.2009.6

    OpenUrlCrossRefPubMed
69. 69.↵
    Genetics and epigenetics of addiction DrugFacts. National Institute on Drug Abuse. August 5, 2019. Accessed July 16, 2022. nida.nih.gov/publications/drugfacts/genetics-epigenetics-addiction
70. 70.↵
    1. Webster LR,
    2. Webster RM

    . Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442. doi: 10.1111/j.1526-4637.2005.00072.x

    OpenUrlCrossRefPubMed